Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Pizotifen 250micrograms/5ml oral suspension
0407042Q0AAAEAE
|
Pizotifen malate | Pizotifen malate | Central Nervous System | 179 |
|
Risperdal 1mg tablets
040201030BBAAAA
|
Risperdal | Risperidone | Central Nervous System | 179 |
|
Venlalic XL 300mg tablets
0403040W0BNAEAV
|
Venlalic | Venlafaxine | Central Nervous System | 178 |
|
Haldol Decanoate 50mg/1ml solution for injection ampoules
0402020T0BBAAAA
|
Haldol Decan | Haloperidol decanoate | Central Nervous System | 177 |
|
Melatonin 2.5mg/5ml oral suspension
0401010ADAACGCG
|
Melatonin | Melatonin | Central Nervous System | 177 |
|
Morphine sulfate 15mg/1ml solution for injection ampoules
0407020Q0AAACAC
|
Morphine sulfate | Morphine sulfate | Central Nervous System | 177 |
|
Tramadol 300mg modified-release tablets
040702040AAAMAM
|
Tramadol hydrochloride | Tramadol hydrochloride | Central Nervous System | 177 |
|
Oxycodone 120mg modified-release tablets
0407020ADAAAPAP
|
Oxycodone hydrochloride | Oxycodone hydrochloride | Central Nervous System | 176 |
|
Stiripentol 500mg capsules
0408010AGAAABAB
|
Stiripentol | Stiripentol | Central Nervous System | 176 |
|
Mirapexin 2.1mg modified-release tablets
0409010W0BBAHAH
|
Mirapexin | Pramipexole | Central Nervous System | 173 |
|
Actimorph 1mg orodispersible tablets
0407020Q0BQACGG
|
Actimorph | Morphine sulfate | Central Nervous System | 171 |
|
Manerix 150mg tablets
0403020K0BBAAAA
|
Manerix | Moclobemide | Central Nervous System | 171 |
|
Quviviq 50mg tablets
0401040A0BBABAB
|
Quviviq | Daridorexant | Central Nervous System | 171 |
|
Strattera 25mg capsules
0404000S0BBADAD
|
Strattera | Atomoxetine hydrochloride | Central Nervous System | 171 |
|
Mirapexin 1.57mg modified-release tablets
0409010W0BBAJAJ
|
Mirapexin | Pramipexole | Central Nervous System | 170 |
|
Briviact 75mg tablets
0408010ALBBADAD
|
Briviact | Brivaracetam | Central Nervous System | 169 |
|
Levetiracetam 250mg gran for soln sachets sugar free
0408010A0AAAVAV
|
Levetiracetam | Levetiracetam | Central Nervous System | 169 |
|
Tiagabine 5mg tablets
0408010ABAAAAAA
|
Tiagabine | Tiagabine | Central Nervous System | 169 |
|
Melatonin 1mg capsules
0401010ADAABQBQ
|
Melatonin | Melatonin | Central Nervous System | 168 |
|
Fycompa 10mg tablets
0408010AKBBAEAE
|
Fycompa | Perampanel | Central Nervous System | 167 |
|
Axalid 25mg capsules
0408010AEBFAAAA
|
Axalid | Pregabalin | Central Nervous System | 166 |
|
Midazolam 5mg/0.5ml oromucosal soln pf oral syringes SF
0408020V0AAAVAV
|
Midazolam maleate (Buccal) | Midazolam maleate | Central Nervous System | 166 |
|
Zyprexa 7.5mg tablets
040201060BBABAB
|
Zyprexa | Olanzapine | Central Nervous System | 166 |
|
Axalid 50mg capsules
0408010AEBFABAB
|
Axalid | Pregabalin | Central Nervous System | 164 |
|
Risperdal 2mg tablets
040201030BBABAB
|
Risperdal | Risperidone | Central Nervous System | 163 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.